Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Background

Tasha Francis, Ph.D., an associate in Fish & Richardson’s Twin Cities office, practices intellectual property litigation with an emphasis on patent litigation. Dr. Francis has represented plaintiffs and defendants in cases involving medical devices, biotechnology and pharmaceuticals. In addition, she writes extensively on topics related to the Biologics Price Competition and Innovation Act and life science Post-Grant proceedings. Dr. Francis is licensed to practice law in the state of Minnesota and before the United State Patent and Trademark Office.

Since joining Fish, Dr. Francis has been at the forefront of developing local programming with the Girl Scouts where local troops earn their Inventor’s Badge and Intellectual Property Patch.  The aim of the program is to educate young women on the basic tenets of intellectual property law, specifically copyrights, trademarks, and patents.

Dr. Francis earned her Ph.D. in Chemical Biology from the University of Michigan in 2010, where her thesis focused on the development of small molecule anti-cancer therapeutics.  In 2013, Dr. Francis graduated from the University of Michigan Law School, where she was a contributing editor for the Michigan Telecommunications and Technology Law Review.

Education

J.D., University of Michigan Law School 2013


Ph.D., University of Michigan 2010
Chemical Biology
Phi Kappa Pi, Iota Sigma Pi


B.A., Dartmouth College 2002
Chemistry and Mathematics

Admissions

  • U.S. Patent and Trademark Office 2009
  • Minnesota 2013
  • U.S. District Court for the District of Minnesota

Memberships & Affiliations

​Federal Bar Association
Contributing Editor, Michigan Telecommunications and Technology Law Review​

Other Distinctions

Publications

The Ramifications of Leaving the Patent Dance Floor,” written with Jenny Shmuel, Fish Litigation Blog (August 3, 2017).

Kyle Bass Ends with a Bang: Success in Final PTAB Decision,” written with Tucker N. Terhufen, Fish Post-Grant Alerts (June 20, 2017).

Thought Leaders Gather at 8th Annual ACI Biosimilars Summit,” written with Jenny Shmuel, Fish Litigation Blog (June 14, 2017).

SCOTUS Unravels Some of the BPCIA Enigma — But Questions Remain,” written with Jenny Shmuel, Fish Litigation Blog (June 13, 2017).

Kyle Bass Does Not Seek to Uphold PTAB Decisions on Appeal,” written with Tucker N. Terhufen, Fish Post-Grant Alerts (June 9, 2017).

The Last “Cabilly” Challenge Quietly Settles,” written with Casey Kraning-Rush and Jenny Shmuel, Fish Post-Grant Alerts (May 25, 2017).

Surveying The Current Legal Landscape For Biosimilars, mentioned by author Terry Mahn, who wrote this piece with Lawrence Sung (of Wiley Rein) and Patrick Gallagher (of Duane Morris), Biosimilar Development, (May 3, 2017).

Justices Struggle With BPCIA Enigma, co-written with Jenny Shmuel, Law360 (April 28, 2017).

Protective Agreements Before and During BPCIA Litigation: Prosecution and Regulatory Bars, co-written with Jenny Shmuel and Noori Torabi, Fish Litigation Blog (April 7, 2017).

Recent Developments in Biopharma PTAB Practice,” author with Dorothy Whelan and Will Orlady, NYIPLA (February/March 2017).

Kyle Bass Wins at the PTAB, co-written with Tucker Terhufen, IP Litigator, January/February 2017, Vol. 23, #1

A Mixed Bag for Kyle Bass: Three Wins and Eight Losses at the PTAB, co-written with Tucker Terhufen, Fish Post-Grant Alerts (March 22, 2017).

A Dive Into BPCIA Confidential Info Disclosure Requirements, co-written with Will Orlady, Law 360 (March 15, 2017).

First Biosimilar Monoclonal Antibody in Oncology Granted EU Approval: Implications for the U.S. Market, co-written with Ron Vogel and Jenny Shmuel, Fish Litigation Blog, March 14, 2017.

Rituxan® Patents Resurface at the PTAB, co-written with Casey Kraning-Rush and Jenny Shmuel, Fish Post-Grant Alerts (March 10, 2017).

Mixed Results When New Attribution Standard is Put to the Test with Life Science Divided-Actor Method Claims, co-written with Gina Nellesen and Betsy Flanagan, Fish Litigation Blog, March 3, 2017.

Genentech Seeks “Urgent” Relief from Amgen’s Alleged BPCIA Violations, co-written with Jenny Shmuel, Fish Litigation Blog, February 17, 2017.

Biosimilar Litigants Square Off Before the Supreme Court, co-written with Jenny Shmuel and Gina Nellesen, Fish Litigation Blog, February 16, 2017.

Dance Partners Janssen and Celltrion Face Off in Trial Scheduled for February 2017, co-written with Jasmine De Cock and Jenny Shmuel, Fish Litigation Blog, February 7, 2017.

Inflectra® Biosimilar Patent Litigation—The Remedies Dispute, co-written with a former Fish attorney, Fish Litigation Blog, February 3, 2017.

Janssen Files Opening Appeal Brief in Attempt to Revive Remicade® Patent, co-written with Jenny Shmuel, Fish Litigation Blog, February 02, 2017.

Biosimilars: What to Expect in 2017, co-written with Jenny Shmuel, Fish Litigation Blog, January 23, 2017.

Patent Challengers Must Show Harm to Appeal Final PTAB Decisions, co-written with Jenny Shmuel and Gina Nellesen, Fish Post-Grant Blog, January 20, 2017.

Biosimilars: Looking Back and Looking Ahead, co-written with Jenny Shmuel and Gina Nellesen, Bloomberg Law: Pharmaceutical Law & Industry Report,  January 18, 2017.

Amgen v. Sandoz: SCOTUS to Solve the Riddle Wrapped in a Mystery Inside an Enigma, co-written with Jenny Shmuel, Fish Litigation Blog (January 17, 2017).

Confidentiality in BPCIA Cases, co-written with Jenny Shmuel and Karrie Wheatley, Fish Litigation Blog (January 05, 2017).

Celgene Asks PTAB to Reconsider Adverse Final Written Decisions, co-written with Tucker N. Terhufen, Fish Post-Grant Alerts (December 5, 2016).

Amgen Opposes Apotex’s Petition for Certiorari, co-written with Jenny Shmuel and Gina Nellesen, Fish Litigation Blog (November 18, 2016).

Amgen Crystallizes Disagreement in Appeal of Discovery Row, co-written with Jenny Shmuel and Gina Nellesen, Fish Litigation Blog (November 17, 2016).

New Developments in AbbVie’s BPCIA Suit Targeting Amgen’s Humira® Biosimilar, co-written with Tucker N. Terhufen and Jenny Shmuel, Fish Litigation Blog (November 14, 2016).

Kyle Bass is on a Roll: Four More Wins at the PTAB, co-written with Tucker N. Terhufen, Fish Post-Grant Alerts (November 1, 2016).

Kyle Bass Wins at the PTAB, co-written with Tucker N. Terhufen, Fish Post-Grant Alerts (October 25, 2016).

Mylan and the Biosimilars Council Urge Supreme Court to Overturn Amgen v. Apotex, co-written with Gina Nellesen and Jenny Shmuel, Fish Litigation Blog (October 21, 2016).

Biogen Dodges IPR Bullet on Key Tysabri® Patents, co-written with Casey Kraning-Rush and Jenny Shmuel, Fish Litigation Blog (October 20, 2016).

Kyle Bass Wins at the PTAB, co-written with Tucker Terhufen, Fish Patent Blog (October 20, 2016).

Amgen Appeals Loss of Neulasta® and Neupogen® Litigation, co-written with Jenny Shmuel and Ethan Rubin, Fish Litigation Blog (October 7, 2016).

Amgen’s Humira Biosimilar Becomes the Fourth FDA Approved Biosimilar, co-written with Jenny Shmuel and Holly Chamberlain, Fish Litigation Blog (September 27, 2016).

FDA to Hold Public Meeting on Biosimilar User Fees, co-written with Rachel Bandli, Fish Litigation Blog (September 21, 2016).

Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Ruling. co-written with Jenny Shmuel and Holly Chamberlain, Fish Litigation Blog (September 20, 2016).

The Dance Continues: Apotex Petitions the Supreme Court for Review, co-written with Jenny Shmuel and Will Orlady, Fish Litigation Blog (September 19, 2016).

Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars, co-written with Jenny Shmuel, Fish Litigation Blog (September 8, 2016).

FDA Approves Sandoz’s Biosimilar of Enbrel®, co-written with Jenny Shmuel, Fish Litigation Blog (August 31, 2016).

Amgen Can Enforce Notice of Commercial Marketing for Epogen® Biosimilar, co-written with Jenny Shmuel, Fish Litigation Blog (August 8, 2016).

Amgen DJ to Compel Patent Dance Dismissed, co-written with Jenny Shmuel, Fish Litigation Blog (July 26, 2016).

Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotex, co-written with Jenny Shmuel and Alex Pechette, Fish Litigation Blog (June 14, 2016).

Notice of Commercialization Is Only Effective After FDA-Approval Regardless of Whether Parties Dance, co-written with Jenny Shmuel, Fish Litigation Blog (July 11, 2016).

You Can’t Patent Dance Your Way Out of Biosimilar Notice, co-written with Jenny Shmuel, Law360 (July 8, 2016).

Janssen Uses Manufacturing Info Obtained in BPCIA Litigation to Target Supplier, co-written with Jenny Shmuel and Alex Pechette, Fish Litigation Blog (June 17, 2016).

Amgen v. Sandoz—The Biosimilars Battle Continues, co-written with Jenny Shmuel and Sarah Jack, Fish Litigation Blog (June 15, 2016).

Live from the ACI Biosimilar Conference, Fish Litigation Blog (June 15, 2016).

Janssen Continues BPCIA Litigation Against Celltrion But Eyes New Target, co-written with Jenny Shmuel and Alex Pechette, Fish Litigation Blog (June 10, 2016).

Janssen Seeks Expedited Trial Following FDA Approval of Remicade Biosimilar, co-written with Jenny Shmuel, Fish Litigation Blog (April 13, 2016).

Spangenberg Finds Partner to Target Nucynta® Patent, Fish Post-Grant Alerts (January 28, 2016).

Will the Trans-Pacific Partnership Derail Biologics? co-written with Terry Mahn, Pharmaceutical Compliance Monitor (December 4, 2015).

Kyle Bass Group Gets PTAB To Review 4 Celgene Patents, Fish Post-Grant Alerts (October 28,2015).

First Bass IPR Instituted, Fish Post-Grant Alerts (October 8, 2015).

PTAB Denies Sanctions Against Bass, Fish Post-Grant Alerts (September 28, 2015).

Kyle Bass’ IPRs: Are You Next?, Fish Post-Grant Alerts (September 8, 2015).

Injunction Denied, Sandoz Cleared to Launch, Fish Litigation Blog (September 2, 2015).

BPCIA Dance Partners Request En Banc Rehearing and Amgen Seeks Temporary Injunction, Fish Litigation Blog (August 27, 2015).

PTAB Denies First Two Bass IPR Petitions, Fish Post-Grant Alerts (August 25, 2015).

Bass IPR Activity Heats Up in August, Fish Post-Grant Alerts (August 21, 2015).

Bass Opposes Sanctions and Defends His Actions at the PTAB, Fish Post-Grant Alerts (August 12, 2015).

Choose Your Court, co-written with Dorothy Whelan, Life Sciences Intellectual Property Review(July 23, 2015).

The Confusing and Often Contradictory World of Pleading Defenses and Counterclaims in Patent Cases, co-written with Conrad Gosen, IPO Daily News™ (June 25, 2015).

Celgene Seeks Sanctions Against Bass, Fish Post-Grant Alerts (June 11, 2015).

Kyle Bass Files Fifteenth IPR Petition, Fish Post-Grant Alerts (May 22, 2015).

Preparing for Biosimilar Litigation, Fish Litigation Blog (May 12, 2015).

Amgen v. Sandoz: To Dance or Not?Fish Litigation Blog (May 11, 2015).

Non-Practicing Entities as IPR Petitioners in BioPharma, Fish Post-Grant Alerts, Fish Litigation Blog (April 23, 2015).

Fish & Girl Scouts Collaboration, Fish Articles (April 14, 2015).

Patenting Orphan Drugs>, Fish Litigation Blog (January 30, 2015).

Limelight v. Akamai: A software case worthy of biotech’s attention, Fish Litigation Blog (April 29, 2014).

Lexicography may not override ordinary meaning in the absence of clear disclaimer, Fish Litigation Blog (February 26, 2014).

Fed. Cir. adopts more flexible standards for awarding attorneys’ fees, Fish Litigation Blog (January 13, 2014).

Francis, T.M., Continued employment as sufficient consideration for pre-invention assignment agreements. State Bar of Michigan IPLS Proceedings, 2014, 25, 1-5.

Francis, T.M., Target identification and validation of a novel family of anti-inflammatory 1,4-benzodiazepine-2,5-diones. Dissertations Abstracts International, 2010.

Nicolaou, K.C., Brenzovich, W.E., Bulger, P.G. and Francis, T.M., Synthesis of iso-epoxy-amphidinolide N and des-epoxy-caribenolide I Structures. Initial Forays. Org. & Biomol. Chem. 2006, 11, 2119.

Francis, T.M.; Sundberg, T.B.; Cleary, J.; Groendyke, T.; Opipari, A.W.; Glick, G.D. Identification of cytotoxic, T-cell-selective 1,4-benzodiazepine-2,5-diones. Bio. Org. Med. Chem. Lett. 2006, 16, 2432.

Zhou, J.; Zong, C.; Francis, T.M.; Braun, C.L. Radiative Exciplexes of 1,2,4,5-Tetracyanobenzene with Sterically Hindered Alkylbenzenes. J. Phys. Chem. A. 2003, 107, 8319-8326.

Zhou, J.; Findley, B.R.; Francis, T.M.; Nytko, E.A.; Braun, C.L. The Solution Dynamics of Photoinduced Geminate Radical Ion Pairs: Free Ion Formation. Chemical Physics Letters. 2002, 362, 63-71.

Bruckner, Christian; McCarthy, J.R.; Daniell, H.W.; Pendon, Z.D.; Ilagan, R.P.; Francis, T.M.; Ren, L.; Birge, R.R.; Frank, H.A. A Spectroscopic and Computational Study of the Singlet and Triplet Excited States of Synthetic -Functionalized Chlorins. Chemical Physics. 2003, 294, 285-303.

What's trending with Tasha

Filter by
Fish Litigation Blog
August 3, 2017
The Ramifications of Leaving the Patent Dance Floor
The Ramifications of Leaving the Patent Dance Floor
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Patent Blog
June 14, 2017
Tasha Francis, Will Orlady and Dorothy Whelan Author NYIPLA Article, "Recent Developments in Biopharma PTAB Practice"
Tasha Francis, Will Orlady and Dorothy Whelan Author <i>NYIPLA</i> Article,
Authors: Will Orlady, Dorothy P. Whelan, Tasha M. Francis, Ph.D.
Fish Litigation Blog
June 13, 2017
SCOTUS Unravels Some of the BPCIA Enigma — But Questions Remain
SCOTUS Unravels Some of the BPCIA Enigma — But Questions Remain
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
Fish Patent Blog
May 25, 2017
The Last “Cabilly” Challenge Quietly Settles
The Last “Cabilly” Challenge Quietly Settles
Authors: Casey Kraning-Rush, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
Fish Litigation Blog
April 28, 2017
Law360: Justices Struggle With BPCIA Enigma
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
April 7, 2017
Protective Agreements Before and During BPCIA Litigation: Prosecution and Regulatory Bars
Protective Agreements Before and During BPCIA Litigation:  Prosecution and Regulatory Bars
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Fish Litigation Blog
March 15, 2017
Law 360: A Dive Into BPCIA Confidential Info Disclosure Requirements
Law 360: A Dive Into BPCIA Confidential Info Disclosure Requirements
Authors: Will Orlady, Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
March 14, 2017
First Biosimilar Monoclonal Antibody in Oncology Granted EU Approval: Implications for the U.S. Market
First Biosimilar Monoclonal Antibody in Oncology Granted EU Approval:  Implications for the U.S. Market
Authors: Jenny Shmuel, Ph.D., Ron Vogel, Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
March 3, 2017
Mixed Results When New Attribution Standard is Put to the Test with Life Science Divided-Actor Method Claims
Webinar: Patentability of Software After Alice
Authors: Betsy Flanagan, Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
June 14, 2017
Thought Leaders Gather at 8th Annual ACI Biosimilars Summit
Thought Leaders Gather at 8th Annual ACI Biosimilars Summit
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Event
May 23rd, 2017 | 1:00 pm EDT
Webinar: BPCIA Guidance from the Federal Circuit and the Supreme Court
Webinar: BPCIA Guidance from the Federal Circuit and the Supreme Court
Webinar
News
March 22, 2017
A Mixed Bag for Kyle Bass: Three Wins and Eight Losses at the PTAB
Articles
load more topics